Ore­gon's Cas­cade Chem­istry looks to boost its Amer­i­can-made API pro­duc­tion with $14M in­vest­ment

Amid height­ened calls for Amer­i­can-made drugs, a suite of con­tract man­u­fac­tur­ers are mak­ing big in­vest­ments to boost sup­ply. Now, an Ore­gon CD­MO is step­ping up to the plate to grow its API con­tract busi­ness.

Cas­cade Chemisty will triple its to­tal floor space with a $14 mil­lion in­vest­ment, the com­pa­ny said in a press re­lease. Site con­struc­tion is al­ready un­der­way on a 28,000 square-foot build­ing, which will in­clude suites for Phase I and Phase II man­u­fac­tur­ing with flow hy­dro­gena­tion and re­ac­tors up to 400 liters.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.